Khon Kaen, Thailand

Khon Kaen University

www.kku.ac.th
Khon Kaen, Thailand

Khon Kaen University or KKU is a public research university in Thailand. It was the first university established in Northeastern Thailand and remains the oldest and largest university in the region. The university is a central hub of education in northeast Thailand. It is an internationally recognized university in Asia. These days, KKU offers a wide range of programs: Its comprehensive academic program offers 105 undergraduate majors, along with 129 master's degree programs and 59 doctoral programs. Khon Kaen University was ranked 21st in South East Asia by Time Higher Education in 2009, and the 4th in Thailand by The Office of Higher Education Commission. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

The incidence of bile duct cancer (cholangiocarcinoma) is increasing year on year throughout the world. More than 2,500 people will be diagnosed with this cancer in the UK in the next year and for most this will be a lethal diagnosis. Fewer than 5% will survive for 12 months – an appalling statistic which hasn’t changed in decades.   In light of this, UK’s leading charity dedicated to bile duct cancer, AMMF, will bring together scientists, researchers, medics and patients from across the globe at its third Conference and Information Day dedicated exclusively to bile duct cancer, on 11 May, 2017 at the Radisson Blu Hotel, Stansted Airport, Essex.   Amongst AMMF-funded researchers who will be presenting updates on their work at this year’s AMMF Conference, will be Professor Stuart Forbes from the MRC Centre for Regenerative Medicine, explaining his research into the signals Wnt and Notch which are thought to drive the growth of cholangiocarcinoma. In addition, Dr Luke Boulter from Edinburgh’s Institute of Genetics & Molecular Medicine will be discussing his very promising work, “Discovering driver mutations in cholangiocarcinoma using forward genetics”.   The work of both these teams, if successful, could bring closer some ‘game changing’ treatment targets for cholangiocarcinoma.   This year’s Conference also sees Professor Narong Khuntikeo from Khon Kaen University, Thailand presenting the work of the CASCAP (Cholangiocarcinoma Screening and Care Program) team in north east Thailand, which has the world’s highest incidence of cholangiocarcinoma. Professor Khuntikeo is vice-president of the Cholangiocarcinoma Foundation of Thailand and recipient of The Royal College of Surgeons of Thailand Outstanding Surgeon Honours Award 2016.   Conference to highlight latest surgical treatments and targeted therapies for bile duct cancer   Other topics to be addressed at this year’s Conference will include the latest surgical developments in the treatment of bile duct cancer, updates on clinical trials, and the status of targeted therapies for cholangiocarcinoma.   Helen Morement, founder and CEO of the AMMF explains, “Although bile duct cancer is the second most common primary liver cancer in the world, with an increasing incidence globally, and despite its appalling survival rates due to late diagnosis and few treatment options, it remains poorly understood and under researched. The Conference is a key platform for an international panel of experts to share news and information about clinical studies and latest research. The findings bring the prospect of early diagnosis and more effective treatments one step closer.”   Helen continues, “We are especially delighted that Professor Richard Syms from Imperial College London, who is also working collaboratively with the team at Khon Kaen University on an AMMF-funded internal imaging project, will be presenting the positive early results of this work at the Conference.”   Bile duct cancer is a rare cancer that occurs in the bile duct in or outside the liver. With few noticeable and often misunderstood symptoms, this disease is frequently diagnosed too late for surgery, the only potentially curative treatment. Without treatment fewer than 5% of patients will survive beyond 12 months. Cases of bile duct cancer have risen steeply and steadily across the world over the past decades. According to the recent NCIN/Cancer52 report, 2,161 people died in 2013 from this disease in England alone.   About AMMF AMMF (The Alan Morement Memorial Fund) was founded and registered as a charity with the Charity Commission in 2002 (registered charity no 1091915). AMMF is the UK’s only cholangiocarcinoma charity, dedicated to tackling this devastating cancer on all fronts: providing information and support, campaigning to raise awareness, and encouraging and supporting research.   In recent years an enormous and extremely worrying worldwide increase in cholangiocarcinoma’s incidence has been noted. Latest figures show there were 2,161 deaths caused by cholangiocarcinoma in 2013 in England alone (NCIN/Cancer52 report). The incidence appears to be increasing across all age groups, including younger people, and the cause of this ongoing increase is unknown. Much more research is desperately needed.   AMMF is dedicated to bringing about improvement for the cholangiocarcinoma patient, working closely throughout the UK with patients, families, carers, clinicians, healthcare professionals, researchers, politicians and policy makers. For more information visit: www.ammf.org.uk (registered charity no.1091915).   About the Conference & Information Day AMMF is not making a charge for attendance at the conference; it is open to all who have an interest in cholangiocarcinoma. However, if delegates would like to help to offset costs, a suggested donation of £25 per head can be made to the AMMF 2017 Conference Justgiving Page by clicking here: https://www.justgiving.com/fundraising/AMMF-Charity2   About the MRC Centre for Regenerative Medicine at the University of Edinburgh The MRC Centre for Regenerative Medicine (CRM) is a research institute based at the University of Edinburgh. Scientists and clinicians study stem cells, disease and tissue repair to advance human health. For more information please visit: http://www.crm.ed.ac.uk/   About the MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh (IGMM). The MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh (IGMM), formed in 2007, is a strategic partnership of the: • MRC Human Genetics Unit (MRC HGU) • Cancer Research UK Edinburgh Centre (CRUK EC) • Centre for Genomic and Experimental Medicine (CGEM).   The IGMM constitutes one of the largest aggregates of human molecular genetics and biology research capacity in the UK with over 70 Principal Investigators and 500 staff and PhD students. By pooling the resources and complementary skills of the constituent centres, IGMM brings together the scientific expertise, technology and support services needed to maximise scientific discovery.   The Institute enables rapid translation of basic scientific discoveries into new treatments, clinical guidelines and innovative products that have significant impact on the society in the UK and Worldwide.   For more information please visit: http://www.ed.ac.uk/igmm/about   About CASCAP (Cholangiocarcinoma Screening and Care Program), Thailand CASCAP stands for the Cholangiocarcinoma Screening and Care Program. The aim of CASCAP is to accelerate the transition of CCA from being a neglected disease to being on the public health national agenda. Its specific focus is to develop and make available a high quality database of compiled information about CCA in the region, to determine the optimal screening program for early diagnosis to maximize the success of surgical treatment, and to increasing both the quality of life and long-term survival of patients. For more information please visit http://www.cascap.info/main/index.php/about-us/about-cascap.html National Cancer Intelligence Network (NCIN) and Cancer52 For more information please visit: http://www.ncin.org.uk/publications/rare_and_less_common_cancers For media inquiries and interviews, please contact: ESTHER PORTA, 3CommPR LONDON, United Kingdom 07870439158 esther@3commpr.co.uk The post Why latest work from top UK cancer researchers could hold potential for future ‘game-changing’ treatments for rare bile duct cancer, cholangiocarcinoma appeared first on PR Fire.


News Article | May 11, 2017
Site: www.eurekalert.org

Identifying areas of particular high impact is an important step to improving the environmental sustainability of production systems. Insects have been heralded as the foods of the future - and now the first study to measure the environmental impacts and identify hotspots associated with commercial insect production has been published. Cricket farming can be a sustainable way to produce animal source foods The study demonstrated that cricket farming can be a sustainable means of producing animal source foods. The study compared cricket production in Thailand to broiler chicken production. Fifteen different environmental impacts were investigated including global warming potential, resource depletion and eutrophication. In most cases, cricket production had a lower impact than broiler chicken production. The major reason for the lower impacts is the fact that the feed conversion into animal protein is more efficient, as the production of the feed is a major hotspot in both systems. "This research is very timely, as there are many different stakeholders interested in farmed insects. Many people have seen insects as a means of lowering the environmental burden of animal production. Insects, in many cases, can be comparable to meat and fish in terms of nutritional value. The fact that we have shown here that they can be produced more environmentally sustainably than meat means that they represent a massive potential for lowering the impact of the food production" explains lead author, PhD student Afton Halloran of the University of Copenhagen's Department of Nutrition, Exercise and Sports. Possibility to become even more environmentally sustainable The study also demonstrated the need for further research to look into alternative ways of feeding the crickets: "While crickets consume plant matter in the wild, farmers started to use commercial chicken feeds because they saw that the crickets grew faster. Unfortunately, the production of feed ingredients like maize and soy can have detrimental effects on the environment. Luckily our colleagues at the Department of Entomology, Khon Kaen University are looking into other feed sources farmed crickets, such as different kinds of plants and waste products" concludes PhD student Afton Halloran. In Thailand, cricket farming has been occurring for nearly 20 years with 20,000 farms scattered throughout the northeastern and northern parts of the country. Around the world, there are over 2,000 insect species that are regularly eaten. Most of these species are harvested from the wild, but around nine insect species are currently farmed for food and feed. The study is published as the article "Life cycle assessment of cricket farming in north-eastern Thailand" in the 'Journal of Cleaner Production'. The study is a part of GREEiNSECT, a research project investigating the contribution of insects for food and feed to green economy. GREEiNSECT is led by Dr. Nanna Roos of the University of Copenhagen and funded by Danida, Ministry of Foreign Affairs. PhD student Afton Halloran Department of Nutrition, Exercise and Sports University of Copenhagen Mail: aha@nexs.ku.dk telephone: +45 5017 0440 Associate Professor Nanna Roos Department of Nutrition, Exercise and Sports University of Copenhagen Mail: nro@nexs.ku.dk telephone: +45 3028 8988 Associate Professor Sander Bruun Department of Plant and Environmental Science University of Copenhagen Mail: sab@plen.ku.dk telephone: +45 2940 6537 Communications Officer Kristian Levring Madsen Department of Nutrition, Exercise and Sports University of Copenhagen Mail: kma@nexs.ku.dk telephone: +45 4048 1684


Aromdee C.,Khon Kaen University
Expert Opinion on Therapeutic Patents | Year: 2012

Introduction: Andrographis paniculata Nees, Acanthaceae, is a well-recognised medicinal plant in Asia. It has been reported to possess a variety of biological activities. The main constituent of A. paniculata is andrographolide (Androg). Since the plant is known to treat many diseases, Androg was modified for many biological activities to treat and prevent a variety of diseases. Area covered: This review surveys the patents from 2006 to 15 November 2011 for antibacterials, antivirals, antidiabetic, anticancer, analgesic, antipyretic and anti-inflammatory analogues. SciFinder database was used to search for the patent work using the keywords 'andrographolide', 'andrographolide derivatives', 'andrographolide analogues' and later additional limits, that is, 'patent' and 'years', 'Clinical trial' and 'years' were searched. Espacenet was also searched for 'andrographolide', 'andrographolide derivatives' and 'andrographolide analogues'. Expert opinion: Androg is a good pharmacophore for many pharmacological activities. Esterification at either one or more of the three hydroxyls with short/long chains, heterocyclic, aromatic fatty acids was attempted and tested for a variety of activities. Most of the responses were positive. Other modifications were epoxidation at Δ 7(18) along with esterifications with various carboxylic acids for anticancer activity. 15-Alkylidene analogues were investigated for α-glucosidase inhibition. The improvement of activities have not yet been proven to be due to the increase in the ability of analogues to reach the targets as prodrugs or the new feature structures fitted to the receptors. It seems that substitution with active compounds, such as lipoic acid, is a new trend for modification. © 2012 Informa UK, Ltd.


Pattanittum P.,Khon Kaen University
The Cochrane database of systematic reviews | Year: 2013

Lateral elbow pain, or tennis elbow, is a common condition that causes pain in the elbow and forearm. Although self-limiting, it can be associated with significant disability and often results in work absence. It is often treated with topical and oral non-steroidal anti-inflammatory drugs (NSAIDs). This is an update of a review first published in 2002 (search date October 11, 2012). To assess the benefits evidence was obtained from three trials (153 participants) suggesting that topical NSAIDs were significantly more effective than placebo with respect to pain in the short term (mean difference -1.64, 95% confidence interval (CI) -2.42 to -0.86) and number needed to treat to benefit (7 (95% CI 3 to 21) on a 0 to 10 scale). Low-quality evidence was obtained from one trial (85 participants) indicating that significantly more participants report fair, good or excellent effectiveness with topical NSAIDs versus placebo at 28 days (14 days of therapy) (risk ratio (RR) 1.49, 95% CI 1.04 to 2.14). No participants withdrew as the result of adverse events, but some studies reported mild adverse effects such as rash in 2.5% of those exposed to topical NSAIDs compared with 1.3% of those exposed to placebo.Low-quality and conflicting evidence regarding the benefits of oral NSAIDs obtained from two trials could not be pooled. One trial found significantly greater improvement in pain compared with placebo, and the other trial found no between-group differences; neither trial found differences in function. One trial reported a withdrawal due to adverse effects for a participant in the NSAIDs group. Use of oral NSAIDs was associated with increased risk of gastrointestinal side effects compared with placebo in one trial in the review. Another trial reported discontinuation of treatment due to gastrointestinal side effects in four participants taking NSAIDs, and another participant developed an allergic reaction in response to oral NSAIDs.Very scant and conflicting evidence regarding the comparative effects of oral NSAIDs and glucocorticoid injection was obtained. One trial reported a significant improvement in pain with glucocorticoid injection, and another found no between-group differences; treatment success was similar between groups (RR of fair, good or excellent effectiveness 0.74; 95% CI 0.43 to 1.26). Transient pain may occur following injection. There remains limited evidence from which to draw firm conclusions about the benefits or harms of topical or oral NSAIDs in treating lateral elbow pain. Although data from five placebo-controlled trials suggest that topical NSAIDs may be beneficial in improving pain (for up to 4 weeks), non-normal distribution of data and other methodological issues precluded firm conclusions. Some people may expect a mild transient skin rash. Evidence about the benefits of oral NSAIDs has been conflicting, although oral NSAID use may result in gastrointestinal adverse effects in some people. No direct comparisons between oral and topical NSAIDs were available. Some trials demonstrated greater benefit from glucocorticoid injection than from NSAIDs in the short term, but this was not apparent in all studies and was not apparent by 6 months in the only study that included longer-term outcomes.


Boonmak S.,Khon Kaen University
The Cochrane database of systematic reviews | Year: 2013

Functional endoscopic sinus surgery (FESS) is a minimally invasive technique that is used to treat chronic sinusitis. Small bleeding areas can reduce operative visibility and result in destruction of surrounding structures. Deliberate hypotension (lowering the mean arterial blood pressure to between 50 and 65 mm Hg in normotensive patients) using a range of pharmacological agents during general anaesthesia reduces blood loss in many operations. We aimed to compare the use of the intravenous anaesthetic agent propofol versus other techniques for deliberate hypotension during FESS with regard to blood loss and operative conditions. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 1), MEDLINE (1950 to April 2012), EMBASE (1980 to April 2012), LILACS (1982 to April 2012) and ISI Web of Science (1946 to April 2012). We also searched the reference lists of relevant articles and conference proceedings and contacted the authors of included trials. We sought all randomized controlled trials (RCTs) conducted to compare propofol with other techniques. Our primary outcome was total blood loss (TBL). Other outcomes included surgical field quality, operation time, mortality within 24 hour, complications and failure to reach target blood pressure. Two review authors independently extracted details of trial methodology and outcome data from reports of all trials considered eligible for inclusion. All analyses were made on an intention-to-treat basis where possible. When I(2) was < 40% and the P value from the Chi(2) test was > 0.10, we pooled data by using the fixed-effect model. Otherwise we pooled data by using the random-effects model. We included four studies with 278 participants in the review. Deliberate hypotension with propofol did not decrease TBL (millilitres) when compared with inhalation anaesthetics in either children or adults. Propofol improved the quality of the surgical field by less than one category on a scale from 0 (no bleeding) to 5 (severe bleeding) (mean difference (MD) 0.64 better with propofol, 95% confidence interval (CI) 0.37 to 0.91 better), but no difference in operation time was reported. Failure to lower blood pressure to target was less common in the propofol group (relative risk of failure with propofol (RR) 0.24, 95% CI 0.09 to 0.66). Using propofol to achieve deliberate hypotension may improve the surgical field, but the effect is small. Deliberate hypotension with propofol did not decrease TBL and operation time. RCTs with good quality methodology and large sample size are required to investigate the effectiveness of deliberate hypotension with propofol for FESS.


Muktabhant B.,Khon Kaen University
Cochrane database of systematic reviews (Online) | Year: 2012

Excessive weight gain during pregnancy is associated with multiple maternal and neonatal complications. However, interventions to prevent excessive weight gain during pregnancy have not been adequately evaluated. To evaluate the effectiveness of interventions for preventing excessive weight gain during pregnancy and associated pregnancy complications. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (20 October 2011) and MEDLINE (1966 to 20 October 2011). All randomised controlled trials and quasi-randomised trials of interventions for preventing excessive weight gain during pregnancy. We assessed for inclusion all potential studies we identified as a result of the search strategy. At least two review authors independently assessed trial quality and extracted data. We resolved discrepancies through discussion. We have presented results using risk ratio (RR) for categorical data and mean difference for continuous data. We analysed data using a fixed-effect model. We included 28 studies involving 3976 women; 27 of these studies with 3964 women contributed data to the analyses. Interventions focused on a broad range of interventions. However, for most outcomes we could not combine data in a meta-analysis, and where we did pool data, no more than two or three studies could be combined for a particular intervention and outcome. Overall, results from this review were mainly not statistically significant, and where there did appear to be differences between intervention and control groups, results were not consistent. For women in general clinic populations one (behavioural counselling versus standard care) of three interventions examined was associated with a reduction in the rate of excessive weight gain (RR 0.72, 95% confidence interval 0.54 to 0.95); for women in high-risk groups no intervention appeared to reduce excess weight gain. There were inconsistent results for mean weight gain (reported in all but one of the included studies). We found a statistically significant effect on mean weight gain for five interventions in the general population and for two interventions in high-risk groups.Most studies did not show statistically significant effects on maternal complications, and none reported significant effects on adverse neonatal outcomes. There is not enough evidence to recommend any intervention for preventing excessive weight gain during pregnancy, due to the significant methodological limitations of included studies and the small observed effect sizes. More high-quality randomised controlled trials with adequate sample sizes are required to evaluate the effectiveness of potential interventions.


Aromdee C.,Khon Kaen University
Expert Opinion on Therapeutic Patents | Year: 2014

Introduction: Extraction, isolation and modifications of andrographolide (Androg) is extensively investigated and patented. The prominent activities were vastly modified for anticancer and antivirals. Many products related to Androg are commercially available, thus the section Interaction of Androg and Andrographis paniculata dried extract with drugs is included.Areas covered: The data in this review are searched and selected from SciFinder and Espacenet for the patents, with the keywords: Andrographolide and Andrographolide analogs, and the results were refined by the years.Expert opinion: Modifications of Androg have been done to nearly all of the possible sites, and now screening tests for any new activities had been settled down. Categorizing the analogs that have been developed is not clear cut since some diseases can develop into others, for example, inflammation and some viral infections can develop into cancer. Currently, investigation of the mode of action and the mechanisms at the molecular level are intensively ongoing. Producing new chemotherapeutic agents from Androg looks promising. The main problem of using Androg in therapeutic applications is its insolubility in aqueous media. Those modified analogs esters, ethers or salts, have to be considered for the stability of pharmaceutical preparations, and transformation in biological fluids after administration. Further stages of drug development are required for those promising analogs. © 2014 Informa UK, Ltd.


Lumbiganon P.,Khon Kaen University
BJOG : an international journal of obstetrics and gynaecology | Year: 2014

To assess the proportion of severe maternal outcomes resulting from indirect causes, and to determine pregnancy outcomes of women with indirect causes. Secondary analysis of the WHO Multicountry Survey on Maternal and Newborn Health. A total of 359 health facilities in 29 countries in Africa, Asia, Latin America, and the Middle East. A total of 314 623 pregnant women admitted to the participating facilities. We identified the percentage of women with severe maternal outcomes arising from indirect causes. We evaluated the risk of severe maternal and perinatal outcomes in women with, versus without, underlying indirect causes, using adjusted odds ratios and 95% confidence intervals, by a multilevel, multivariate logistic regression model, accounting for clustering effects within countries and health facilities. Severe maternal outcomes and preterm birth, fetal mortality, early neonatal mortality, perinatal mortality, low birthweight, and neonatal intensive care unit admission. Amongst 314 623 included women, 2822 were reported to suffer from severe maternal outcomes, out of which 20.9% (589/2822; 95% CI 20.1-21.6%) were associated with indirect causes. The most common indirect cause was anaemia (50%). Women with underlying indirect causes showed significantly higher risk of obstetric complications (adjusted odds ratio, aOR, 7.0; 95% CI 6.6-7.4), severe maternal outcomes (aOR 27.9; 95% CI 24.7-31.6), and perinatal mortality (aOR 3.8; 95% CI 3.5-4.1). Indirect causes were responsible for about one-fifth of severe maternal outcomes. Women with underlying indirect causes had significantly increased risks of severe maternal and perinatal outcomes. © 2014 RCOG The World Health Organization retains copyright and all other rights in the manuscript of this article as submitted for publication.


Laopaiboon M.,Khon Kaen University
BJOG : an international journal of obstetrics and gynaecology | Year: 2014

To assess the association between advanced maternal age (AMA) and adverse pregnancy outcomes. Secondary analysis of the facility-based, cross-sectional data of the WHO Multicountry Survey on Maternal and Newborn Health. A total of 359 health facilities in 29 countries in Africa, Asia, Latin America, and the Middle East. A total of 308 149 singleton pregnant women admitted to the participating health facilities. We estimated the prevalence of pregnant women with advanced age (35 years or older). We calculated adjusted odds ratios of individual severe maternal and perinatal outcomes in these women, compared with women aged 20-34 years, using a multilevel, multivariate logistic regression model, accounting for clustering effects within countries and health facilities. The confounding factors included facility and individual characteristics, as well as country (classified by maternal mortality ratio level). Severe maternal adverse outcomes, including maternal near miss (MNM), maternal death (MD), and severe maternal outcome (SMO), and perinatal outcomes, including preterm birth (<37 weeks of gestation), stillbirths, early neonatal mortality, perinatal mortality, low birthweight (<2500 g), and neonatal intensive care unit (NICU) admission. The prevalence of pregnant women with AMA was 12.3% (37 787/308 149). Advanced maternal age significantly increased the risk of maternal adverse outcomes, including MNM, MD, and SMO, as well as the risk of stillbirths and perinatal mortalities. Advanced maternal age predisposes women to adverse pregnancy outcomes. The findings of this study would facilitate antenatal counselling and management of women in this age category. © 2014 RCOG The World Health Organization retains copyright and all other rights in the manuscript of this article as submitted for publication.


Hoang Lan N.,Khon Kaen University
Global health action | Year: 2013

In recent years, cases of breast cancer have been on the rise in Vietnam. To date, there has been no study on the financial burden of the disease. This study estimates the direct medical cost of a 5-year treatment course for women with primary breast cancer in central Vietnam. Retrospective patient-level data from medical records at the Hue Central Hospital between 2001 and 2006 were analyzed. Cost analysis was conducted from the health care payers' perspective. Various direct medical cost categories were computed for a 5-year treatment course for patients with breast cancer. Costs, in US dollars, discounted at a 3% rate, were converted to 2010 after adjusting for inflation. For each cost category, the mean, standard deviation, median, and cost range were estimated. Median regression was used to investigate the relationship between costs and the stage, age at diagnosis, and the health insurance coverage of the patients. The total direct medical cost for a 5-year treatment course for breast cancer in central Vietnam was estimated at $975 per patient (range: $11.7-$3,955). The initial treatment cost, particularly the cost of chemotherapy, was found to account for the greatest proportion of total costs (64.9%). Among the patient characteristics studied, stage at diagnosis was significantly associated with total treatment costs. Patients at later stages of breast cancer did not differ significantly in their total costs from those at earlier stages however, but their survival time was much shorter. The absence of health insurance was the main factor limiting service uptake. From the health care payers' perspective, the Government subsidization of public hospital charges lowered the direct medical costs of a 5-year treatment course for primary breast cancer in central Vietnam. However, the long treatment course was significantly influenced by out-of-pocket payments for patients without health insurance.

Loading Khon Kaen University collaborators
Loading Khon Kaen University collaborators